Invitrogen™ CD18 Monoclonal Antibody (2E6)

Descripción

MA1805 targets CD18 in FACS, IA, and IP applications and shows reactivity with mouse samples. The MA1805 immunogen is cD18. MA1805 detects CD18 which has a predicted molecular weight of approximately 83 kDa. This product is a Low Endotoxin formulation. This product has been tested for endotoxins by limulus amoebocyte lysate (LAL) assay and contains an endotoxin concentration of less than or equal to 10 endotoxin units per milligram (EU/mg).

CD18, also known as the integrin beta 2 subunit, is a 90-95 kDa type I transmembrane protein expressed on all leukocytes. It heterodimerizes with the alpha chains of CD11a, CD11b, CD11c, and CD11d to form various leukocyte (beta2) integrins, which are crucial for cellular adhesion and signaling. The CD18/CD11a complex, known as lymphocyte function-associated antigen-1 (LFA-1), plays a significant role in cellular adhesion and inflammatory reactions. CD18 also forms heterodimers with CD11b (Mac-1, CR3), CD11c, and CD11d, contributing to the processes of cell adhesion and cell-surface mediated signaling. These integrins are essential for proper leukocyte migration and mediating intercellular contacts. The absence of CD18 leads to leukocyte adhesion deficiency type I (LAD1), a condition characterized by impaired leukocyte migration. Severe reduction in CD18 expression can result in the development of a psoriasiform skin disease. CD18 is also a target of Mannheimia (Pasteurella) haemolytica leukotoxin, which can mediate leukotoxin-induced cytolysis. Defects in the CD18 gene are the cause of LAD1, and two transcript variants encoding the CD18 protein have been identified. The integrin-mediated responses are often a composite of the functions of its individual subunits, highlighting the importance of CD18 in immune function and disease.